HopeStage
Back to all studies
CompletedNCT01074632

Meals and lurasidone absorption in schizophrenia

About this titleRead the official source — NCT01074632
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Glendale and 1 more locationSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2009
Recruitment status
Completed
Enrollment listed in the registry
26
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT01074632
Official title
Show the full official title

A Phase 1, Open-Label Study to Determine the Effect of Calories and Fat Content on the Pharmacokinetics of Repeated Dose Lurasidone 120 mg in Subjects With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Glendale · Wichita

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Lurasidone HCl.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies